Cargando…

Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study

LESSONS LEARNED. Clinically applicable tools are needed for treatment selection and repurposing of available protein kinase inhibitors (PKIs) in patients with advanced solid tumors refractory to standard treatment. Using a tyrosine kinase peptide substrate microarray, observed inhibitory activity in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Labots, Mariette, Van der Mijn, Johannes C., Dekker, Henk, Ruijter, Rita, Pham, Thang V., Van der Vliet, Hans J., Van der Hoeven, Jacobus J.M., Meijer, Gerrit A., Verheul, Henk M.W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AlphaMed Press 2018
Materias:	Clinical Trial Results
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6263134/ https://www.ncbi.nlm.nih.gov/pubmed/30018133 http://dx.doi.org/10.1634/theoncologist.2018-0263

Ejemplares similares

A Phase I Open‐Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26–104/RFASE in Patients with Advanced Solid Malignancies
por: Goedegebuure, Ruben S.A., et al.
Publicado: (2020)

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
por: Labots, Mariette, et al.
Publicado: (2016)

Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome
por: Labots, Mariette, et al.
Publicado: (2020)

Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma
por: van Linde, Myra E., et al.
Publicado: (2022)

Advancing wide implementation of precision oncology: A liquid nitrogen‐free snap freezer preserves molecular profiles of biological samples
por: van der Wijngaart, Hanneke, et al.
Publicado: (2023)

Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer
por: Johnson, Faye M, et al.
Publicado: (2022)

Adjuvant Zoledronic Acid in High‐Risk Giant Cell Tumor of Bone: A Multicenter Randomized Phase II Trial
por: Lipplaa, Astrid, et al.
Publicado: (2019)

A Phase Ib, Open‐Label Study of Dalantercept, an Activin Receptor‐Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma
por: Abou‐Alfa, Ghassan K., et al.
Publicado: (2018)

Chemoprevention in Patients with Peutz‐Jeghers Syndrome: Lessons Learned
por: de Brabander, Justin, et al.
Publicado: (2018)

A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
por: Carlo, Maria I., et al.
Publicado: (2016)

Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High‐Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial
por: Maughan, Benjamin L., et al.
Publicado: (2018)

INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases
por: Beekhof, Robin, et al.
Publicado: (2019)

A Phase I Dose‐Escalation Study of Linsitinib (OSI‐906), a Small‐Molecule Dual Insulin‐Like Growth Factor‐1 Receptor/Insulin Receptor Kinase Inhibitor, in Combination with Irinotecan in Patients with Advanced Cancer
por: Davis, S. Lindsey, et al.
Publicado: (2018)

Analysis of AKT and ERK1/2 protein kinases in extracellular vesicles isolated from blood of patients with cancer
por: van der Mijn, Johannes C., et al.
Publicado: (2014)

Direct admission versus interhospital transfer for revascularisation in non‐ST‐segment elevation myocardial infarction
por: van Steenbergen, Gijs J., et al.
Publicado: (2023)

Safety and Activity of Sorafenib in Addition to Vinflunine in Post‐Platinum Metastatic Urothelial Carcinoma (Vinsor): Phase I Trial
por: Shah, Carl‐Henrik, et al.
Publicado: (2018)

Time dependent effect of cold ischemia on the phosphoproteome and protein kinase activity in fresh-frozen colorectal cancer tissue obtained from patients
por: Buffart, Tineke E., et al.
Publicado: (2021)

Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma
por: Grierson, Patrick M, et al.
Publicado: (2022)

Efficacy and Safety of Apatinib in Patients with Recurrent or Refractory Melanoma
por: Yuan, Shumin, et al.
Publicado: (2022)

Sorafenib for Patients with Hepatocellular Carcinoma and Child‐Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study
por: Labeur, Tim A., et al.
Publicado: (2019)

Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors
por: Rovithi, Maria, et al.
Publicado: (2019)

A specific microRNA profile as predictive biomarker for systemic treatment in patients with metastatic colorectal cancer
por: Poel, Dennis, et al.
Publicado: (2020)

A Single‐Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer
por: Chen, Xiaofeng, et al.
Publicado: (2019)

S‐1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial
por: Chen, Ye, et al.
Publicado: (2019)

A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer
por: Segar, Jennifer M., et al.
Publicado: (2019)

A Phase II Study of Tumor Ablation in Patients with Metastatic Sarcoma Stable on Chemotherapy
por: Hirbe, Angela C., et al.
Publicado: (2018)

Phase II Trial of Trifluridine/Tipiracil Plus Irinotecan in Patients with Advanced, Refractory Biliary Tract Carcinoma
por: Tella, Sri Harsha, et al.
Publicado: (2023)

Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan‐Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
por: Edelman, Gerald, et al.
Publicado: (2018)

Prolonged Pemetrexed Infusion Plus Gemcitabine in Refractory Metastatic Colorectal Cancer: Preclinical Rationale and Phase II Study Results
por: Passardi, Alessandro, et al.
Publicado: (2017)

Avelumab, a PD‐L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma
por: Kazandjian, Dickran, et al.
Publicado: (2021)

A Phase II Study of Apatinib in Patients with Chemotherapy‐Refractory Esophageal Squamous Cell Carcinoma (ESO‐Shanghai 11)
por: Chu, Li, et al.
Publicado: (2021)

A Phase I Dose‐Escalation Study of Clofarabine in Patients with Relapsed or Refractory Low‐Grade or Intermediate‐Grade B‐Cell or T‐Cell Lymphoma
por: Foss, Francine Marie, et al.
Publicado: (2018)

Cladribine with Granulocyte Colony‐Stimulating Factor, Cytarabine, and Aclarubicin Regimen in Refractory/Relapsed Acute Myeloid Leukemia: A Phase II Multicenter Study
por: Wang, Hua, et al.
Publicado: (2020)

A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone‐ and/or Enzalutamide‐Refractory Metastatic Castration‐Resistant Prostate Cancer
por: Wei, Xiao X., et al.
Publicado: (2018)

Phase Ib/II Study of Biweekly TAS‐102 in Combination with Bevacizumab for Patients with Metastatic Colorectal Cancer Refractory to Standard Therapies (BiTS Study)
por: Satake, Hironaga, et al.
Publicado: (2020)

A Phase Ib Dose-Escalation Study of LCL161 Plus Oral Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
por: Johnson, Melissa L, et al.
Publicado: (2023)

A Randomized, Double‐Blind, Placebo‐Controlled, Phase II Study of Regorafenib Versus Placebo in Advanced/Metastatic, Treatment‐Refractory Liposarcoma: Results from the SARC024 Study
por: Riedel, Richard F., et al.
Publicado: (2020)

Randomized Phase II Trial of Parsatuzumab (Anti‐EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First‐Line Metastatic Colorectal Cancer
por: García‐Carbonero, Rocío, et al.
Publicado: (2017)

Randomized Phase II Study of Cabazitaxel Versus Methotrexate in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-Based Therapy
por: Machiels, Jean-Pascal, et al.
Publicado: (2016)

Caenorhabditis Intervention Testing Program: the tyrosine kinase inhibitor imatinib mesylate does not extend lifespan in nematodes
por: Coleman-Hulbert, Anna L., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ctthgt1p3iv2p0df8kbg9keo5u